Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that the adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine (for adults, adolescents and children), developed by its wholly-owned subsidiary Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biotech”), has completed Phase I clinical trial preparations and officially initiated its Phase I clinical trial, with the first subject successfully enrolled. The vaccine — a preventive biologic registered under Chemical/Biologics Classification 2.6 as an injectable — is designed to induce immune responses for the prevention of pertussis (whooping cough), diphtheria, and tetanus across age groups, a combination for which no domestic manufacturer’s product has yet been approved in China, according to the National Medical Products Administration (NMPA) website.
Clinical Trial Milestone
| Item | Detail |
|---|---|
| Company | Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) |
| Developer | Beijing Minhai Biotechnology Co., Ltd. (wholly-owned subsidiary) |
| Product | Adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine (for adults, adolescents and children) |
| Dosage Form | Injection |
| Registration Classification | Preventive biologic, Category 2.6 |
| Trial Phase | Phase I – initiated; first subject enrolled |
| Trial Design | Randomized, blinded, controlled |
| Study Objective | Safety and immunogenicity in healthy subjects aged 6 years and above |
| Domestic Competition | No approved comparable domestic product per NMPA website query |
Vaccine Profile
- Product Type: Adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine — a multi-antigen (“combination”) preventive vaccine produced by Minhai Biotech.
- Population: Applicable to adults, adolescents and children, an unusually broad intended age span for a single combination product.
- Mechanism: Following vaccination, the product is designed to elicit immune responses against pertussis, diphtheria, and tetanus — three vaccine-preventable diseases historically controlled through childhood immunization but requiring lifelong booster coverage.
- Component Technology: The “(component)” designation reflects a purified-component acellular pertussis formulation approach, the modern standard replacing whole-cell pertussis vaccines for improved reactogenicity profiles. (Domain background.)
- Domestic First Potential: Per the company’s query of the NMPA website, no domestic manufacturer currently has an approved adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine for adults, adolescents and children in China.
Phase I Trial Design
- Design: Randomized, blinded, controlled trial.
- Population: Healthy subjects aged 6 years and above — extending enrollment beyond adults to include the adolescent and pediatric age range.
- Endpoints: Evaluation of safety and immunogenicity; specific cohort sizes, control vaccine, and immunogenicity assays were not disclosed.
- Status: Preparations completed and first subject successfully enrolled, marking a phased R&D milestone for the product.
Disease & Market Context – Pertussis, Diphtheria and Tetanus Across the Lifespan
- Waning Immunity: Protection from childhood pertussis-diphtheria-tetanus immunization wanes over time, which is why international immunization practice relies on adolescent and adult booster doses of acellular combination vaccines. (Domain background.)
- Pertussis Resurgence: Several countries have reported pertussis re-emergence among adolescents and adults despite high childhood coverage, renewing interest in lifecycle booster strategies. (Domain background; no specific epidemiologic data were disclosed.)
- China Adult-Vaccine Gap: The absence of an approved domestic combination product for adults, adolescents and children highlights an underserved segment of China’s immunization market, where adult vaccination remains comparatively underdeveloped.
- Combination Vaccine Value: Multi-component combinations simplify immunization schedules and improve coverage versus separate single-antigen injections — a core rationale for the product’s development.
Market Impact & Outlook
- Full-Age-Range Pipeline Coverage: If successfully developed, the vaccine would complement the company’s existing Phase III adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine (pediatric program), forming full-age-range pipeline coverage from children through adults.
- Portfolio Expansion: The program advances Kangtai’s layout in two strategic domains — multi-component combination vaccines and adult vaccines — supporting the company’s stated foundation for sustained, steady development.
- First-Mover Potential: With no approved domestic comparable product, the vaccine positions Minhai Biotech/Kangtai as a potential first domestic entrant in this combination category.
- Competitive & Execution Risks: Phase I entry is an early-stage milestone; safety, immunogenicity, and eventual efficacy must still be demonstrated through subsequent trial phases, and regulatory approval is not assured.
- Next Steps: Active advancement of the Phase I study; trial sites, enrollment targets, timelines, and R&D investment figures were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Kangtai Biological Products’ adsorbed acellular pertussis‑diphtheria‑tetanus (component) combination vaccine, including Phase I clinical outcomes, subsequent development phases, and potential contributions to the company’s combination and adult vaccine portfolios. Vaccine development entails objective failure risk; initiation of a Phase I trial and first-subject enrollment do not guarantee safety, immunogenicity, regulatory approval, or commercialization. Actual results may differ due to risks including clinical trial outcomes, regulatory review, competitive products, and immunization policy dynamics.-Fineline Info & Tech
